Sanofi stock: analysis & valuation

SAN.PADrug Manufacturers - GeneralFranceData as of Nov 15, 2026
Metrics analysis · Drug Manufacturers - General

Sanofi SAN.PA

Price 87.60 EUR −0.43%Market cap 105.2 bn EUR52 weeks 69.75 – 90.07
Forward P/E
9.3x
Industry 15.9x
EV/EBITDA
8.1x
Industry 13.6x
Revenue growth
15.7%
Industry 5.8%
Operating margin
22.3%
Industry 31.5%
Return on equity
5.7%
Industry 20.2%
Free cash flow yield
7.9%
Industry 3.8%

What does Sanofi do?

Sanofi is a globally active pharmaceutical group headquartered in Paris. The company researches, develops, produces and sells prescription medicines and vaccines. The focus is on immunology and inflammatory diseases, rare diseases, neurology and oncology. It also has a large vaccines division, which includes influenza, pediatric and combination vaccines as well as protection against respiratory syncytial virus.

Sanofi generates revenue mainly through the sale of patent-protected medicines and vaccines to hospitals, pharmacies, wholesalers, and government health systems and vaccination programs. Established medicines and over-the-counter health products also form part of the portfolio. In terms of competition, Sanofi is among the large diversified pharmaceutical companies and is one of the world's leading vaccine providers. New active ingredients come from its own research and from collaborations and licensing agreements with biotechnology companies.

Score profile

Quality3.6
Valuation8.3
Growth8.6
Financial strength6.9
Momentum9.1

Rank vs. Drug Manufacturers - General (18 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.

Metrics compared with the industry

On profitability and quality, Sanofi ranks below average in the group Drug Manufacturers - General (3.6/10). On growth, the company ranks among the best in the group Drug Manufacturers - General (8.6/10). On valuation (higher = cheaper), the stock ranks among the best in the group Drug Manufacturers - General (8.3/10). On financial strength, Sanofi ranks above average in the group Drug Manufacturers - General (6.9/10).

MetricStockGroup medianRanking
Forward P/E9.3x15.9xbetter than 92 %
Trailing P/E25.3x26.9xbetter than 66 %
PEG ratio1.8x3.3xbetter than 79 %
EV/EBITDA8.1x13.6xbetter than 81 %
Price/sales2.1x4.2xbetter than 81 %
Price/book1.4x5.5xbetter than 97 %
Revenue growth15.7%5.8%better than 92 %
Earnings growth9.4%-2.8%better than 79 %
Gross margin74.3%74.2%better than 53 %
Operating margin22.3%31.5%better than 19 %
Net margin8.2%14.3%better than 36 %
Return on equity5.7%20.2%better than 36 %
Debt/equity27.1%105.3%better than 92 %
Current ratio1.1x1.4xbetter than 36 %
Free cash flow yield7.9%3.8%better than 81 %
Dividend yield4.7%2.3%–
Payout ratio119.1%63.3%–
Beta0.260.31–

Valuation: what is Sanofi worth?

Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Sanofi a model range of 150.41 EUR to 217.42 EUR per share.

Price 87.60 EUR
Analysts 96.36 EUR
Fair value range 150.41 EUR – 217.42 EURMidpoint 155.24 EUR (+77.2% vs. price)

23 analysts, average rating “Buy”, average price target 96.36 EUR (+10.0%).

The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.

What the business depends on

  • Success depends heavily on the market penetration of key patent-protected medicines, particularly in immunology.
  • The vaccines business benefits from government vaccination programs, seasonal demand and its position as an established large-scale provider.
  • A well-stocked development pipeline and successful approvals secure long-term replacements for products whose patent protection is expiring.

Risks

  • Patent expirations and competition from generics or biosimilars can significantly reduce revenue from established medicines.
  • Clinical trials or approval procedures can fail, which writes off high research investments.
  • Price regulation, reimbursement rules and political intervention in health systems weigh on pricing, especially in the US and Europe.

What to look for with Sanofi

The development of the revenue share of core products relative to the pipeline is informative, as it shows dependence on individual medicines and the need for replacements.

Full AI analysis of Sanofi

The AI evaluates all the numbers above and turns them into an assessment with a score, strengths and weaknesses, a fair value range and risks – from €1.99; Plus (€4.99) adds business model, moat and scenarios, Pro (€9.99) also peer comparison and reverse DCF. See an example.

Analyze a stock

Results in minutes
1 Choose a stock
2 Choose the depth

See what you get first: Example Compact (Apple) PDF Plus example (Microsoft) PDF Example Pro (NVIDIA) PDF

3 Delivery
Secure payment via Stripe Report by email + PDF No subscription

Frequently asked questions about Sanofi stock

What is the P/E ratio of Sanofi stock?

Based on expected earnings, Sanofi trades at a P/E of 9.3x, compared with a median of 15.9x for the peer group Drug Manufacturers - General. Based on the earnings of the last twelve months it is 25.3x. (data as of Nov 15, 2026)

Does Sanofi pay a dividend?

Yes. The dividend yield is currently 4.7%, with a payout ratio of 119.1% of earnings.

Is Sanofi stock undervalued?

Measured by valuation metrics (P/E, EV/EBITDA, price/sales, PEG), Sanofi is currently valued cheaper than most companies in the group Drug Manufacturers - General (valuation score 8.3 out of 10). Our model calculations (DCF and industry multiples) give a range of 150.41 EUR to 217.42 EUR per share at a price of 87.60 EUR. This is a model calculation, not an investment recommendation.

What do analysts say about Sanofi stock?

23 analysts have an average price target of 96.36 EUR (+10.0% vs. the current price); the average rating is “Buy”. Analyst targets are opinions and change frequently.

Comparable stocks

All information without guarantee. Metrics from public market data, updated daily; company profile written editorially with the help of AI. Not investment advice and not a solicitation to buy or sell securities.